Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
As per available reports about Breast cancer is a Cancer that forms in tissues of the breast. The most common type of breast cancer, 3 relevant journals, 619 Conference Proceedings, 175 Open Access Articles, 76 National Symposiums are presently dedicated exclusively to Cancer Field.
Breast cancer is a kind of cancer that develops from breast cells.Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. A malignant tumor can spread to other parts of the body. A breast cancer that started off in the lobules is known as lobular carcinoma, while one that developed from the ducts is called ductal carcinoma. Breast cancer is the most common invasive cancer in females worldwide. It accounts for 16% of all female cancers and 22.9% of invasive cancers in women. 18.2% of all cancer deaths worldwide, including both males and females, are from breast
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
Breast cancer rates are much higher in developed nations compared to developing ones. There are several reasons for this, with possibly life-expectancy being one of the key factors - breast cancer is more common in elderly women; women in the richest countries live much longer than those in the poorest nations. The different lifestyles and eating habits of females in rich and poor countries are also contributory factors, experts believe
The 2014 San Antonio Breast Cancer Symposium is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer. As exciting strides are made in the field of breast cancer research and treatment our program continues to present essential up-to-the minute information combined with engrossing discussion for basic, translational and clinical cancer research professionals. The aim of the breast health promotion workshops is to allow relaxed and interactive discussion of breast awareness
When drugs are used to reduce the risk of cancer in healthy people, it’s called chemoprevention. This is an important area of cancer research . Many clinical studies have shown that the drugs tamoxifen and raloxifene reduce the risk of breast cancer in women known to have an increased risk. The main use of tamoxifen is to treat hormone receptor-positive breast cancer When given after a cancer that is hormone receptor-positive has been completely removed by surgery, tamoxifen lowers the chance that the cancer will come back later and helps patients live longer. It also lowers the chance that a new cancer will develop in the other breast. Raloxifene is a drug that was first approved by the FDA to prevent and treat osteoporosis (bone thinning) in women past menopause. Raloxifene helps make bones stronger by acting like estrogen in bone tissue. Like tamoxifen, it also acts as an anti-estrogen in breast tissue. Because it doesn’t act much like estrogen in the uterus, it has a much lower risk of causing cancer of the uterus than tamoxifen. It may also cause fewer problems with serious blood clots. Most doctors recommend that women take tamoxifen or raloxifene for 5 years to lower their risk of breast cancer. The risk was lower during the 5 years the women took the drugs and the lower risk lasted a few years after they’d finished. Researchers are still looking at how long the cancer-lowering effects last.
The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.
This page will be updated regularly.
This page was last updated on July 6, 2020